In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other worst high-risk high-reward growth stocks to buy. On March 14, Tom Lee managing ...

Jones covers the Healthcare sector ... See the top stocks recommended by analysts >> Capricor Therapeutics (CAPR) In a report released today, Leland Gershell from Oppenheimer reiterated a Buy ...

The FDA granted the SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for ...

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with a price target of $43.00. The company’s shares ...

Capricor Therapeutics (NASDAQ:CAPR) just reported results for the first quarter of 2024. Capricor Therapeutics reported earnings per share of -31 cents. This was below the analyst estimate for EPS ...

With deramiocel's BLA submission and solid data, CAPR presents a compelling investment opportunity, trading below projected sales estimates despite recent price increases. …deramiocel was ...

In this article, we are going to take a look at where Capricor Therapeutics, Inc. (NASDAQ:CAPR) stands against other best small-cap growth stocks to buy now. On November 4, 2024, Nick Sheridan ...